Press Release
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Share
LATESTNEWS
-
YolTech Presented Proof-of-Concept Data from Clinical Trial of YOLT-202 in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026
Sep 07, 2026
-
YolTech to Present Late-Breaking Proof-of-Concept Clinical Data from YOLT-202 Clinical Trial in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026
Sep 05, 2026
-
YolTech to Present Positive Data from Clinical Trial of YOLT-201 in ATTR-CM Patients at European Society of Cardiology Congress 2026
Aug 27, 2026
